Technology And Business

TransADMET The program offers a better means to predict response preclinical ADMET in human being. In each model, key genes have been eliminated or replaced by their human counterparts a “improving the pharmacokinetics and safety evaluation of drug candidates by generating research results that are more predictive of human beings. “Together, Taconic and CXR Biosciences are trained investigators with sophisticated new tools that can revolutionize drug discovery and provide a strong competitive advantage,” said Todd Little, President and CEO of Taconic. “Our new models allow researchers transADMET progress in drug discovery more effectively, minimize the chances of failure at the last stage and improve time-to-market with viable new drug therapies.” “The innovative models transADMET transform pharmaceutical research and evaluation of chemical safety, allowing scientists to more accurately reflect the human situation in preclinical studies, thus reducing the likelihood of problems later in clinical trials, “said Tom Shepherd, CEO of CXR Biosciences. “Taconic’s decision to settle here to develop this platform to establish a unique ability CXR and world leader in translational research in Scotland.” Rhona Allison, senior director of life sciences, Scottish Enterprise, said: “Despite the difficult economic conditions, the field of life sciences in Scotland has continued to grow and develop in recent years.

Taconic Investment in this specialized center is a strong indication of continued confidence in Scotland as a great place for life sciences. ” TransADMET program is the culmination of an effort five years and $ 13 million funded by ITI Life Sciences. CXR Biosciences transADMET validated models, while TaconicArtemis acted as the main generator of new models. About Taconic Taconic Farms, Inc. was founded in 1952 as a family business in the Hudson River Valley in New York. Since then, the company became one of the largest suppliers of laboratory rodents in the world, being famous for the breeding of rats and mice continuously well-defined and high quality.

Taconic’s expertise in the design and special generation of genetically modified mice, the mice and rat breeding, barrier systems, animal health and genetics serves as support for researchers engaged in drug development using in vivo models . Taconic has six breeding facilities and three service laboratories in the United States and Europe, a staff of more than 1,000 employees and a commitment to technological innovation. Additional information about Taconic is available through its sitioa About CXR Biosciences Founded in 2001, CXR Biosciences has used its collaborative approach, ownership patterns and cutting-edge skills to help their clients, whatever their size, to resolve issues regarding the selection of drug candidates or the safety of the compounds. CXR pre develops technology platforms that are more predictive of drug response in humans, and provides special services in the areas of preclinical drug development and toxicology research. The company maintains business relations with more than sixty customers and partners, including pharmaceutical companies, chemical companies, biotechnology companies and major universities and research institutions.